NPI: 1295743060 · GLEN COVE, NY 11542 · Community/Retail Pharmacy · NPI assigned 08/04/2006
Authorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
| Authorized Official | CUSACK, MICHELE (SENIOR VP & CFO) |
| NPI Enumeration Date | 08/04/2006 |
Other providers sharing the same authorized official: CUSACK, MICHELE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 228 | $11K |
| 2019 | 4,843 | $305K |
| 2020 | 15,628 | $1.00M |
| 2021 | 27,903 | $1.69M |
| 2022 | 32,592 | $1.68M |
| 2023 | 34,025 | $1.73M |
| 2024 | 25,665 | $1.30M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 7,604 | 7,099 | $1.47M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 5,627 | 5,248 | $976K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6,285 | 5,062 | $733K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7,225 | 1,813 | $559K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,708 | 2,511 | $488K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,656 | 1,586 | $332K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,669 | 1,637 | $322K |
| 36415 | Collection of venous blood by venipuncture | 18,069 | 8,964 | $287K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 5,198 | 1,323 | $261K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,151 | 1,128 | $260K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1,577 | 1,560 | $211K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1,753 | 1,728 | $198K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,053 | 1,015 | $198K |
| 80053 | Comprehensive metabolic panel | 7,582 | 6,962 | $135K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,540 | 1,511 | $130K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 804 | 776 | $118K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,802 | 1,687 | $117K |
| 76641 | 1,317 | 1,148 | $117K | |
| 76830 | Ultrasound, transvaginal | 666 | 661 | $71K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 287 | 282 | $49K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1,751 | 1,726 | $46K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 341 | 336 | $39K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 146 | 146 | $38K |
| 71046 | Radiologic examination, chest; 2 views | 1,346 | 1,316 | $33K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 180 | 179 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2,563 | 2,418 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 756 | 663 | $26K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,069 | 948 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,279 | 1,225 | $23K |
| J3490 | Unclassified drugs | 2,178 | 2,057 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,804 | 1,667 | $22K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,524 | 1,436 | $20K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 323 | 91 | $18K |
| C1889 | Implantable/insertable device, not otherwise classified | 75 | 75 | $18K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 179 | 178 | $17K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 172 | 154 | $16K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 52 | 52 | $16K |
| 0225U | 1,358 | 1,227 | $15K | |
| 97161 | 131 | 131 | $15K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 3,816 | 3,520 | $14K |
| 86850 | 480 | 467 | $13K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 900 | 708 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,627 | 3,382 | $11K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 15 | 15 | $10K |
| 86900 | 486 | 473 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,085 | 996 | $9K |
| 71250 | 71 | 71 | $9K | |
| 80061 | Lipid panel | 848 | 845 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 661 | 652 | $8K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 63 | 63 | $7K |
| 71045 | Radiologic examination, chest; single view | 2,136 | 2,052 | $7K |
| 86901 | 454 | 442 | $7K | |
| 76536 | 78 | 78 | $7K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 857 | 844 | $6K |
| 77080 | 77 | 77 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5,697 | 5,243 | $4K |
| C9399 | Unclassified drugs or biologicals | 100 | 99 | $4K |
| 73562 | 196 | 190 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 401 | 380 | $3K |
| 87631 | 65 | 65 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 480 | 430 | $3K |
| 73610 | 157 | 154 | $3K | |
| 85027 | 2,151 | 2,021 | $3K | |
| 73630 | 121 | 115 | $2K | |
| J2704 | Injection, propofol, 10 mg | 1,084 | 1,080 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,625 | 1,552 | $2K |
| 85610 | 767 | 740 | $2K | |
| 83880 | 90 | 88 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,786 | 1,687 | $2K |
| 86769 | 53 | 52 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | 598 | 590 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 49 | 38 | $1K |
| 73130 | 25 | 24 | $1K | |
| 81025 | 586 | 564 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 626 | 623 | $1K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 40 | 12 | $1K |
| 72100 | 38 | 38 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 595 | 591 | $1K |
| 73110 | 38 | 37 | $1K | |
| 73030 | 52 | 50 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,232 | 2,070 | $976.15 |
| 84702 | 826 | 788 | $946.53 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 439 | 438 | $928.73 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 627 | 625 | $911.16 |
| 81001 | 1,950 | 1,866 | $894.91 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 792 | 787 | $864.02 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 590 | 587 | $859.37 |
| J7170 | Injection, emicizumab-kxwh, 0.5 mg | 13 | 13 | $800.24 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 19 | 19 | $789.24 |
| 88307 | 12 | 12 | $782.47 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 267 | 248 | $775.14 |
| G0008 | Administration of influenza virus vaccine | 128 | 128 | $736.80 |
| 36000 | 30 | 30 | $624.92 | |
| 84484 | 1,445 | 1,349 | $611.80 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 307 | 284 | $590.03 |
| 83690 | 2,032 | 1,891 | $559.85 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 623 | 621 | $542.16 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 20 | 20 | $478.81 |
| 72040 | 15 | 14 | $473.98 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 587 | 572 | $451.49 |
| 85730 | 507 | 496 | $332.08 | |
| 82962 | 610 | 540 | $268.45 | |
| 87581 | 20 | 20 | $249.02 | |
| 87486 | 20 | 20 | $249.02 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 77 | 69 | $192.90 |
| 83735 | 370 | 349 | $171.56 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 27 | 26 | $129.43 |
| 86803 | 15 | 15 | $110.30 | |
| 81002 | 141 | 91 | $96.28 | |
| 85379 | 69 | 69 | $60.72 | |
| J2060 | Injection, lorazepam, 2 mg | 33 | 30 | $53.10 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 12 | 12 | $30.72 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 18 | 18 | $27.02 |
| 81003 | 46 | 43 | $23.30 | |
| 88312 | 49 | 49 | $13.18 | |
| 87081 | 14 | 14 | $0.00 | |
| 87040 | 15 | 14 | $0.00 | |
| 83605 | 13 | 12 | $0.00 |